nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Methazolamide—glaucoma	0.0649	0.131	CbGbCtD
Sitaxentan—CYP2C9—Diclofenamide—glaucoma	0.0627	0.127	CbGbCtD
Sitaxentan—CYP2C9—Dorzolamide—glaucoma	0.0606	0.122	CbGbCtD
Sitaxentan—CYP2C19—Timolol—glaucoma	0.0552	0.112	CbGbCtD
Sitaxentan—CYP2C9—Methazolamide—glaucoma	0.054	0.109	CbGbCtD
Sitaxentan—CYP3A4—Pilocarpine—glaucoma	0.0465	0.0939	CbGbCtD
Sitaxentan—CYP3A4—Brinzolamide—glaucoma	0.0365	0.0737	CbGbCtD
Sitaxentan—CYP3A4—Dorzolamide—glaucoma	0.0352	0.0712	CbGbCtD
Sitaxentan—CYP3A4—Methazolamide—glaucoma	0.0314	0.0634	CbGbCtD
Sitaxentan—CYP3A4—Acetazolamide—glaucoma	0.0251	0.0507	CbGbCtD
Sitaxentan—CYP3A4—Clonidine—glaucoma	0.0227	0.0459	CbGbCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.01	0.085	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.00719	0.0609	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.00685	0.058	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelin Pathways—MYLK—glaucoma	0.00524	0.0444	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.00491	0.0415	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—EDN1—glaucoma	0.00427	0.0362	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—MYLK—glaucoma	0.00375	0.0318	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.00228	0.0193	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelin Pathways—EDN1—glaucoma	0.00211	0.0179	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—PTGFR—glaucoma	0.00202	0.0171	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—OPN4—glaucoma	0.00176	0.0149	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.00163	0.0138	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—PTGFR—glaucoma	0.00159	0.0134	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.00157	0.0133	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—EDN1—glaucoma	0.00151	0.0128	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.00149	0.0126	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00142	0.012	CbGpPWpGaD
Sitaxentan—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.00137	0.0116	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.00136	0.0115	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelin Pathways—NOS3—glaucoma	0.00129	0.0109	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	0.00127	0.0108	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—OPN4—glaucoma	0.00126	0.0107	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—EDN1—glaucoma	0.00126	0.0107	CbGpPWpGaD
Sitaxentan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.00125	0.0106	CbGpPWpGaD
Sitaxentan—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.00125	0.0106	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.00123	0.0104	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.00117	0.00987	CbGpPWpGaD
Sitaxentan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.00114	0.00962	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—PTGFR—glaucoma	0.00113	0.00961	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.00113	0.00954	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.00107	0.00902	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—MMP1—glaucoma	0.00106	0.00896	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.00105	0.00889	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—SMO—glaucoma	0.00102	0.00862	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00101	0.00859	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000974	0.00825	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—NOS3—glaucoma	0.000921	0.0078	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	0.000909	0.00769	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—EDN1—glaucoma	0.000901	0.00763	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—OPN4—glaucoma	0.000888	0.00752	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000877	0.00743	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000835	0.00707	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—PTGFR—glaucoma	0.0008	0.00677	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—MMP1—glaucoma	0.000757	0.00641	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000752	0.00636	CbGpPWpGaD
Sitaxentan—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—glaucoma	0.00075	0.00635	CbGpPWpGaD
Sitaxentan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—glaucoma	0.000733	0.0062	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—OPN4—glaucoma	0.000636	0.00538	CbGpPWpGaD
Sitaxentan—CYP2C19—Tamoxifen metabolism—CYP1B1—glaucoma	0.000633	0.00536	CbGpPWpGaD
Sitaxentan—CYP2C9—Tamoxifen metabolism—CYP1B1—glaucoma	0.000577	0.00489	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTGFR—glaucoma	0.000572	0.00485	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—EDN1—glaucoma	0.000527	0.00446	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—EDN1—glaucoma	0.00052	0.00441	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—OPN4—glaucoma	0.000502	0.00425	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000489	0.00414	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	0.000471	0.00399	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—OPN4—glaucoma	0.000456	0.00386	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—C3—glaucoma	0.000455	0.00385	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PTGFR—glaucoma	0.000452	0.00383	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.000431	0.00365	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTGFR—glaucoma	0.00041	0.00347	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—SMO—glaucoma	0.000403	0.00341	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—EDN1—glaucoma	0.000395	0.00335	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000392	0.00332	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LRP12—glaucoma	0.000388	0.00329	CbGpPWpGaD
Sitaxentan—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000381	0.00322	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—EDN1—glaucoma	0.000377	0.00319	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—EDN1—glaucoma	0.000372	0.00315	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—OPN4—glaucoma	0.000359	0.00304	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.000349	0.00296	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000344	0.00291	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	0.000337	0.00286	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—OPN4—glaucoma	0.000326	0.00276	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—C3—glaucoma	0.000325	0.00276	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PTGFR—glaucoma	0.000323	0.00274	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—APOE—glaucoma	0.000322	0.00272	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000316	0.00268	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.000305	0.00258	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTGFR—glaucoma	0.000294	0.00249	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—SMO—glaucoma	0.000289	0.00244	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000288	0.00244	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—LRP12—glaucoma	0.000278	0.00235	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000273	0.00231	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.00027	0.00228	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—OPN4—glaucoma	0.000269	0.00228	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—EDN1—glaucoma	0.000266	0.00225	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000259	0.00219	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HEYL—glaucoma	0.00025	0.00212	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.00025	0.00212	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000249	0.00211	CbGpPWpGaD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000246	0.00208	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTGFR—glaucoma	0.000242	0.00205	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—C3—glaucoma	0.000232	0.00197	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000222	0.00188	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.000218	0.00185	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—SMO—glaucoma	0.000207	0.00175	CbGpPWpGaD
Sitaxentan—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000203	0.00172	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000202	0.00171	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—OPN4—glaucoma	0.000193	0.00163	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—EDN1—glaucoma	0.00019	0.00161	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RPTOR—glaucoma	0.00019	0.00161	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NCK2—glaucoma	0.000184	0.00156	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HEYL—glaucoma	0.000179	0.00152	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTGFR—glaucoma	0.000173	0.00147	CbGpPWpGaD
Sitaxentan—Thrombocytopenia—Pilocarpine—glaucoma	0.000167	0.000431	CcSEcCtD
Sitaxentan—Tachycardia—Pilocarpine—glaucoma	0.000166	0.00043	CcSEcCtD
Sitaxentan—Dyspepsia—Brimonidine—glaucoma	0.000166	0.00043	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—C3—glaucoma	0.000166	0.00141	CbGpPWpGaD
Sitaxentan—Angina pectoris—Timolol—glaucoma	0.000166	0.000429	CcSEcCtD
Sitaxentan—Hypotension—Brinzolamide—glaucoma	0.000166	0.000428	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000164	0.00139	CbGpPWpGaD
Sitaxentan—Tension—Clonidine—glaucoma	0.000164	0.000423	CcSEcCtD
Sitaxentan—Insomnia—Dorzolamide—glaucoma	0.000163	0.000422	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Brimonidine—glaucoma	0.000163	0.000421	CcSEcCtD
Sitaxentan—Fatigue—Brimonidine—glaucoma	0.000163	0.000421	CcSEcCtD
Sitaxentan—Anorexia—Pilocarpine—glaucoma	0.000163	0.00042	CcSEcCtD
Sitaxentan—Feeling abnormal—Acetazolamide—glaucoma	0.000162	0.000419	CcSEcCtD
Sitaxentan—Hypersensitivity—Apraclonidine—glaucoma	0.000162	0.000419	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000162	0.00137	CbGpPWpGaD
Sitaxentan—Nervousness—Clonidine—glaucoma	0.000162	0.000419	CcSEcCtD
Sitaxentan—Pain—Brimonidine—glaucoma	0.000162	0.000417	CcSEcCtD
Sitaxentan—Visual impairment—Betaxolol—glaucoma	0.000161	0.000415	CcSEcCtD
Sitaxentan—Insomnia—Brinzolamide—glaucoma	0.00016	0.000414	CcSEcCtD
Sitaxentan—Somnolence—Dorzolamide—glaucoma	0.00016	0.000414	CcSEcCtD
Sitaxentan—Muscle spasms—Clonidine—glaucoma	0.00016	0.000414	CcSEcCtD
Sitaxentan—Hypotension—Pilocarpine—glaucoma	0.000159	0.000412	CcSEcCtD
Sitaxentan—Dysuria—Timolol—glaucoma	0.000159	0.000411	CcSEcCtD
Sitaxentan—Dyspepsia—Dorzolamide—glaucoma	0.000159	0.00041	CcSEcCtD
Sitaxentan—Dyspepsia—Travoprost—glaucoma	0.000158	0.000409	CcSEcCtD
Sitaxentan—Asthenia—Apraclonidine—glaucoma	0.000158	0.000408	CcSEcCtD
Sitaxentan—Somnolence—Brinzolamide—glaucoma	0.000158	0.000407	CcSEcCtD
Sitaxentan—Decreased appetite—Dorzolamide—glaucoma	0.000157	0.000405	CcSEcCtD
Sitaxentan—Urticaria—Acetazolamide—glaucoma	0.000156	0.000404	CcSEcCtD
Sitaxentan—Tremor—Clonidine—glaucoma	0.000156	0.000404	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HDAC9—glaucoma	0.000156	0.00132	CbGpPWpGaD
Sitaxentan—Dyspepsia—Brinzolamide—glaucoma	0.000156	0.000403	CcSEcCtD
Sitaxentan—Eye disorder—Betaxolol—glaucoma	0.000156	0.000403	CcSEcCtD
Sitaxentan—Body temperature increased—Acetazolamide—glaucoma	0.000156	0.000402	CcSEcCtD
Sitaxentan—Fatigue—Dorzolamide—glaucoma	0.000156	0.000402	CcSEcCtD
Sitaxentan—Tinnitus—Betaxolol—glaucoma	0.000156	0.000402	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Travoprost—glaucoma	0.000155	0.000401	CcSEcCtD
Sitaxentan—Fatigue—Travoprost—glaucoma	0.000155	0.0004	CcSEcCtD
Sitaxentan—Flushing—Betaxolol—glaucoma	0.000155	0.0004	CcSEcCtD
Sitaxentan—Cardiac disorder—Betaxolol—glaucoma	0.000155	0.0004	CcSEcCtD
Sitaxentan—Ill-defined disorder—Clonidine—glaucoma	0.000155	0.0004	CcSEcCtD
Sitaxentan—Pain—Dorzolamide—glaucoma	0.000154	0.000399	CcSEcCtD
Sitaxentan—Insomnia—Pilocarpine—glaucoma	0.000154	0.000398	CcSEcCtD
Sitaxentan—Decreased appetite—Brinzolamide—glaucoma	0.000154	0.000398	CcSEcCtD
Sitaxentan—Weight decreased—Timolol—glaucoma	0.000154	0.000398	CcSEcCtD
Sitaxentan—Pain—Travoprost—glaucoma	0.000154	0.000397	CcSEcCtD
Sitaxentan—Constipation—Travoprost—glaucoma	0.000154	0.000397	CcSEcCtD
Sitaxentan—Hyperglycaemia—Timolol—glaucoma	0.000154	0.000397	CcSEcCtD
Sitaxentan—Agitation—Clonidine—glaucoma	0.000153	0.000396	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000153	0.000396	CcSEcCtD
Sitaxentan—Asthenia—Bimatoprost—glaucoma	0.000153	0.000395	CcSEcCtD
Sitaxentan—Fatigue—Brinzolamide—glaucoma	0.000153	0.000395	CcSEcCtD
Sitaxentan—Pain—Brinzolamide—glaucoma	0.000152	0.000392	CcSEcCtD
Sitaxentan—Somnolence—Pilocarpine—glaucoma	0.000152	0.000392	CcSEcCtD
Sitaxentan—Angiopathy—Betaxolol—glaucoma	0.000151	0.000391	CcSEcCtD
Sitaxentan—Immune system disorder—Betaxolol—glaucoma	0.000151	0.000389	CcSEcCtD
Sitaxentan—Diarrhoea—Apraclonidine—glaucoma	0.000151	0.000389	CcSEcCtD
Sitaxentan—Malaise—Clonidine—glaucoma	0.00015	0.000389	CcSEcCtD
Sitaxentan—Mediastinal disorder—Betaxolol—glaucoma	0.00015	0.000388	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—EDN1—glaucoma	0.00015	0.00127	CbGpPWpGaD
Sitaxentan—Dyspepsia—Pilocarpine—glaucoma	0.00015	0.000388	CcSEcCtD
Sitaxentan—Feeling abnormal—Dorzolamide—glaucoma	0.000149	0.000384	CcSEcCtD
Sitaxentan—Decreased appetite—Pilocarpine—glaucoma	0.000148	0.000383	CcSEcCtD
Sitaxentan—Feeling abnormal—Travoprost—glaucoma	0.000148	0.000382	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—SMO—glaucoma	0.000148	0.00125	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTT1—glaucoma	0.000148	0.00125	CbGpPWpGaD
Sitaxentan—Conjunctivitis—Timolol—glaucoma	0.000148	0.000381	CcSEcCtD
Sitaxentan—Alopecia—Betaxolol—glaucoma	0.000147	0.000381	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000147	0.00038	CcSEcCtD
Sitaxentan—Feeling abnormal—Brinzolamide—glaucoma	0.000146	0.000378	CcSEcCtD
Sitaxentan—Mental disorder—Betaxolol—glaucoma	0.000146	0.000378	CcSEcCtD
Sitaxentan—Constipation—Pilocarpine—glaucoma	0.000146	0.000377	CcSEcCtD
Sitaxentan—Pain—Pilocarpine—glaucoma	0.000146	0.000377	CcSEcCtD
Sitaxentan—Dizziness—Apraclonidine—glaucoma	0.000146	0.000376	CcSEcCtD
Sitaxentan—Malnutrition—Betaxolol—glaucoma	0.000145	0.000375	CcSEcCtD
Sitaxentan—Urticaria—Dorzolamide—glaucoma	0.000143	0.00037	CcSEcCtD
Sitaxentan—Epistaxis—Timolol—glaucoma	0.000143	0.00037	CcSEcCtD
Sitaxentan—Body temperature increased—Dorzolamide—glaucoma	0.000143	0.000368	CcSEcCtD
Sitaxentan—Tension—Betaxolol—glaucoma	0.000143	0.000368	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—glaucoma	0.000142	0.00121	CbGpPWpGaD
Sitaxentan—Sinusitis—Timolol—glaucoma	0.000142	0.000368	CcSEcCtD
Sitaxentan—Chest pain—Clonidine—glaucoma	0.000142	0.000367	CcSEcCtD
Sitaxentan—Asthenia—Acetazolamide—glaucoma	0.000141	0.000365	CcSEcCtD
Sitaxentan—Dizziness—Bimatoprost—glaucoma	0.000141	0.000365	CcSEcCtD
Sitaxentan—Nervousness—Betaxolol—glaucoma	0.000141	0.000364	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000141	0.000364	CcSEcCtD
Sitaxentan—Urticaria—Brinzolamide—glaucoma	0.000141	0.000364	CcSEcCtD
Sitaxentan—Feeling abnormal—Pilocarpine—glaucoma	0.000141	0.000363	CcSEcCtD
Sitaxentan—Discomfort—Clonidine—glaucoma	0.00014	0.000363	CcSEcCtD
Sitaxentan—Vomiting—Apraclonidine—glaucoma	0.00014	0.000361	CcSEcCtD
Sitaxentan—Muscle spasms—Betaxolol—glaucoma	0.00014	0.000361	CcSEcCtD
Sitaxentan—Hypersensitivity—Brimonidine—glaucoma	0.000139	0.00036	CcSEcCtD
Sitaxentan—Dry mouth—Clonidine—glaucoma	0.000139	0.000359	CcSEcCtD
Sitaxentan—Bradycardia—Timolol—glaucoma	0.000139	0.000358	CcSEcCtD
Sitaxentan—Dermatitis—Apraclonidine—glaucoma	0.000139	0.000358	CcSEcCtD
Sitaxentan—Headache—Apraclonidine—glaucoma	0.000138	0.000356	CcSEcCtD
Sitaxentan—Confusional state—Clonidine—glaucoma	0.000137	0.000355	CcSEcCtD
Sitaxentan—Rhinitis—Timolol—glaucoma	0.000137	0.000353	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—EDN1—glaucoma	0.000136	0.00116	CbGpPWpGaD
Sitaxentan—Oedema—Clonidine—glaucoma	0.000136	0.000352	CcSEcCtD
Sitaxentan—Tremor—Betaxolol—glaucoma	0.000136	0.000352	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—RPTOR—glaucoma	0.000136	0.00115	CbGpPWpGaD
Sitaxentan—Asthenia—Brimonidine—glaucoma	0.000136	0.00035	CcSEcCtD
Sitaxentan—Infection—Clonidine—glaucoma	0.000135	0.000349	CcSEcCtD
Sitaxentan—Body temperature increased—Pilocarpine—glaucoma	0.000135	0.000348	CcSEcCtD
Sitaxentan—Ill-defined disorder—Betaxolol—glaucoma	0.000135	0.000348	CcSEcCtD
Sitaxentan—Diarrhoea—Acetazolamide—glaucoma	0.000135	0.000348	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTT1—glaucoma	0.000135	0.00114	CbGpPWpGaD
Sitaxentan—Rash—Bimatoprost—glaucoma	0.000135	0.000348	CcSEcCtD
Sitaxentan—Dermatitis—Bimatoprost—glaucoma	0.000134	0.000347	CcSEcCtD
Sitaxentan—Oedema peripheral—Timolol—glaucoma	0.000134	0.000347	CcSEcCtD
Sitaxentan—Anaemia—Betaxolol—glaucoma	0.000134	0.000347	CcSEcCtD
Sitaxentan—Headache—Bimatoprost—glaucoma	0.000134	0.000345	CcSEcCtD
Sitaxentan—Nervous system disorder—Clonidine—glaucoma	0.000134	0.000345	CcSEcCtD
Sitaxentan—Thrombocytopenia—Clonidine—glaucoma	0.000133	0.000344	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000133	0.00113	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Dorzolamide—glaucoma	0.000133	0.000343	CcSEcCtD
Sitaxentan—Tachycardia—Clonidine—glaucoma	0.000133	0.000343	CcSEcCtD
Sitaxentan—Hypersensitivity—Travoprost—glaucoma	0.000132	0.000342	CcSEcCtD
Sitaxentan—Skin disorder—Clonidine—glaucoma	0.000132	0.000342	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NCK2—glaucoma	0.000131	0.00111	CbGpPWpGaD
Sitaxentan—Visual impairment—Timolol—glaucoma	0.000131	0.000339	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—C3—glaucoma	0.000131	0.00111	CbGpPWpGaD
Sitaxentan—Malaise—Betaxolol—glaucoma	0.000131	0.000338	CcSEcCtD
Sitaxentan—Nausea—Apraclonidine—glaucoma	0.000131	0.000338	CcSEcCtD
Sitaxentan—Hypersensitivity—Brinzolamide—glaucoma	0.000131	0.000338	CcSEcCtD
Sitaxentan—Vertigo—Betaxolol—glaucoma	0.000131	0.000337	CcSEcCtD
Sitaxentan—Dizziness—Acetazolamide—glaucoma	0.00013	0.000336	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—glaucoma	0.00013	0.0011	CbGpPWpGaD
Sitaxentan—Anorexia—Clonidine—glaucoma	0.00013	0.000335	CcSEcCtD
Sitaxentan—Asthenia—Dorzolamide—glaucoma	0.00013	0.000334	CcSEcCtD
Sitaxentan—Asthenia—Travoprost—glaucoma	0.000129	0.000333	CcSEcCtD
Sitaxentan—Eye disorder—Timolol—glaucoma	0.000127	0.000329	CcSEcCtD
Sitaxentan—Asthenia—Brinzolamide—glaucoma	0.000127	0.000329	CcSEcCtD
Sitaxentan—Hypotension—Clonidine—glaucoma	0.000127	0.000329	CcSEcCtD
Sitaxentan—Tinnitus—Timolol—glaucoma	0.000127	0.000328	CcSEcCtD
Sitaxentan—Nausea—Bimatoprost—glaucoma	0.000127	0.000327	CcSEcCtD
Sitaxentan—Cardiac disorder—Timolol—glaucoma	0.000127	0.000327	CcSEcCtD
Sitaxentan—Hypersensitivity—Pilocarpine—glaucoma	0.000126	0.000325	CcSEcCtD
Sitaxentan—Vomiting—Acetazolamide—glaucoma	0.000125	0.000323	CcSEcCtD
Sitaxentan—Dizziness—Brimonidine—glaucoma	0.000125	0.000323	CcSEcCtD
Sitaxentan—Angiopathy—Timolol—glaucoma	0.000124	0.000319	CcSEcCtD
Sitaxentan—Chest pain—Betaxolol—glaucoma	0.000124	0.000319	CcSEcCtD
Sitaxentan—Diarrhoea—Dorzolamide—glaucoma	0.000123	0.000319	CcSEcCtD
Sitaxentan—Headache—Acetazolamide—glaucoma	0.000123	0.000319	CcSEcCtD
Sitaxentan—Insomnia—Clonidine—glaucoma	0.000123	0.000318	CcSEcCtD
Sitaxentan—Immune system disorder—Timolol—glaucoma	0.000123	0.000318	CcSEcCtD
Sitaxentan—Diarrhoea—Travoprost—glaucoma	0.000123	0.000318	CcSEcCtD
Sitaxentan—Mediastinal disorder—Timolol—glaucoma	0.000123	0.000317	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000123	0.000317	CcSEcCtD
Sitaxentan—Asthenia—Pilocarpine—glaucoma	0.000122	0.000316	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SMO—glaucoma	0.000122	0.00103	CbGpPWpGaD
Sitaxentan—Discomfort—Betaxolol—glaucoma	0.000122	0.000316	CcSEcCtD
Sitaxentan—Diarrhoea—Brinzolamide—glaucoma	0.000121	0.000314	CcSEcCtD
Sitaxentan—Somnolence—Clonidine—glaucoma	0.000121	0.000313	CcSEcCtD
Sitaxentan—Dry mouth—Betaxolol—glaucoma	0.000121	0.000312	CcSEcCtD
Sitaxentan—Alopecia—Timolol—glaucoma	0.00012	0.000311	CcSEcCtD
Sitaxentan—Confusional state—Betaxolol—glaucoma	0.00012	0.000309	CcSEcCtD
Sitaxentan—Mental disorder—Timolol—glaucoma	0.000119	0.000308	CcSEcCtD
Sitaxentan—Dizziness—Dorzolamide—glaucoma	0.000119	0.000308	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—C3—glaucoma	0.000119	0.00101	CbGpPWpGaD
Sitaxentan—Rash—Brimonidine—glaucoma	0.000119	0.000308	CcSEcCtD
Sitaxentan—Dermatitis—Brimonidine—glaucoma	0.000119	0.000307	CcSEcCtD
Sitaxentan—Dizziness—Travoprost—glaucoma	0.000119	0.000307	CcSEcCtD
Sitaxentan—Malnutrition—Timolol—glaucoma	0.000119	0.000307	CcSEcCtD
Sitaxentan—Oedema—Betaxolol—glaucoma	0.000119	0.000306	CcSEcCtD
Sitaxentan—Headache—Brimonidine—glaucoma	0.000118	0.000306	CcSEcCtD
Sitaxentan—Decreased appetite—Clonidine—glaucoma	0.000118	0.000306	CcSEcCtD
Sitaxentan—Infection—Betaxolol—glaucoma	0.000118	0.000304	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP1B1—glaucoma	0.000118	0.000996	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Clonidine—glaucoma	0.000118	0.000304	CcSEcCtD
Sitaxentan—Fatigue—Clonidine—glaucoma	0.000117	0.000303	CcSEcCtD
Sitaxentan—Dizziness—Brinzolamide—glaucoma	0.000117	0.000303	CcSEcCtD
Sitaxentan—Nausea—Acetazolamide—glaucoma	0.000117	0.000302	CcSEcCtD
Sitaxentan—Diarrhoea—Pilocarpine—glaucoma	0.000117	0.000301	CcSEcCtD
Sitaxentan—Tension—Timolol—glaucoma	0.000116	0.000301	CcSEcCtD
Sitaxentan—Pain—Clonidine—glaucoma	0.000116	0.000301	CcSEcCtD
Sitaxentan—Constipation—Clonidine—glaucoma	0.000116	0.000301	CcSEcCtD
Sitaxentan—Nervous system disorder—Betaxolol—glaucoma	0.000116	0.0003	CcSEcCtD
Sitaxentan—Thrombocytopenia—Betaxolol—glaucoma	0.000116	0.0003	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1B1—glaucoma	0.000116	0.000983	CbGpPWpGaD
Sitaxentan—Tachycardia—Betaxolol—glaucoma	0.000116	0.000299	CcSEcCtD
Sitaxentan—Nervousness—Timolol—glaucoma	0.000115	0.000298	CcSEcCtD
Sitaxentan—Skin disorder—Betaxolol—glaucoma	0.000115	0.000297	CcSEcCtD
Sitaxentan—Vomiting—Dorzolamide—glaucoma	0.000115	0.000296	CcSEcCtD
Sitaxentan—Rash—Dorzolamide—glaucoma	0.000114	0.000294	CcSEcCtD
Sitaxentan—Dermatitis—Dorzolamide—glaucoma	0.000114	0.000294	CcSEcCtD
Sitaxentan—Rash—Travoprost—glaucoma	0.000113	0.000293	CcSEcCtD
Sitaxentan—Dermatitis—Travoprost—glaucoma	0.000113	0.000292	CcSEcCtD
Sitaxentan—Headache—Dorzolamide—glaucoma	0.000113	0.000292	CcSEcCtD
Sitaxentan—Anorexia—Betaxolol—glaucoma	0.000113	0.000292	CcSEcCtD
Sitaxentan—Vomiting—Brinzolamide—glaucoma	0.000113	0.000291	CcSEcCtD
Sitaxentan—Dizziness—Pilocarpine—glaucoma	0.000113	0.000291	CcSEcCtD
Sitaxentan—Headache—Travoprost—glaucoma	0.000113	0.000291	CcSEcCtD
Sitaxentan—Nausea—Brimonidine—glaucoma	0.000112	0.00029	CcSEcCtD
Sitaxentan—Feeling abnormal—Clonidine—glaucoma	0.000112	0.00029	CcSEcCtD
Sitaxentan—Rash—Brinzolamide—glaucoma	0.000112	0.000289	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NTRK2—glaucoma	0.000112	0.000947	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HDAC9—glaucoma	0.000112	0.000947	CbGpPWpGaD
Sitaxentan—Dermatitis—Brinzolamide—glaucoma	0.000112	0.000289	CcSEcCtD
Sitaxentan—Headache—Brinzolamide—glaucoma	0.000111	0.000287	CcSEcCtD
Sitaxentan—Hypotension—Betaxolol—glaucoma	0.000111	0.000286	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.00011	0.000931	CbGpPWpGaD
Sitaxentan—Vomiting—Pilocarpine—glaucoma	0.000108	0.00028	CcSEcCtD
Sitaxentan—Urticaria—Clonidine—glaucoma	0.000108	0.000279	CcSEcCtD
Sitaxentan—Body temperature increased—Clonidine—glaucoma	0.000108	0.000278	CcSEcCtD
Sitaxentan—Rash—Pilocarpine—glaucoma	0.000108	0.000278	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—EDN1—glaucoma	0.000108	0.00091	CbGpPWpGaD
Sitaxentan—Dermatitis—Pilocarpine—glaucoma	0.000107	0.000277	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP1B1—glaucoma	0.000107	0.000908	CbGpPWpGaD
Sitaxentan—Insomnia—Betaxolol—glaucoma	0.000107	0.000277	CcSEcCtD
Sitaxentan—Nausea—Dorzolamide—glaucoma	0.000107	0.000277	CcSEcCtD
Sitaxentan—Headache—Pilocarpine—glaucoma	0.000107	0.000276	CcSEcCtD
Sitaxentan—Nausea—Travoprost—glaucoma	0.000107	0.000276	CcSEcCtD
Sitaxentan—Vertigo—Timolol—glaucoma	0.000107	0.000275	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1B1—glaucoma	0.000106	0.000896	CbGpPWpGaD
Sitaxentan—Nausea—Brinzolamide—glaucoma	0.000105	0.000272	CcSEcCtD
Sitaxentan—Dyspepsia—Betaxolol—glaucoma	0.000104	0.00027	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—CA5A—glaucoma	0.000104	0.000876	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NARFL—glaucoma	0.000104	0.000876	CbGpPWpGaD
Sitaxentan—Decreased appetite—Betaxolol—glaucoma	0.000103	0.000266	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Betaxolol—glaucoma	0.000102	0.000264	CcSEcCtD
Sitaxentan—Fatigue—Betaxolol—glaucoma	0.000102	0.000264	CcSEcCtD
Sitaxentan—Pain—Betaxolol—glaucoma	0.000101	0.000262	CcSEcCtD
Sitaxentan—Constipation—Betaxolol—glaucoma	0.000101	0.000262	CcSEcCtD
Sitaxentan—Nausea—Pilocarpine—glaucoma	0.000101	0.000262	CcSEcCtD
Sitaxentan—Chest pain—Timolol—glaucoma	0.000101	0.000261	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.0001	0.000259	CcSEcCtD
Sitaxentan—Hypersensitivity—Clonidine—glaucoma	0.0001	0.000259	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.0001	0.000849	CbGpPWpGaD
Sitaxentan—Discomfort—Timolol—glaucoma	9.98e-05	0.000258	CcSEcCtD
Sitaxentan—Dry mouth—Timolol—glaucoma	9.88e-05	0.000255	CcSEcCtD
Sitaxentan—Asthenia—Clonidine—glaucoma	9.77e-05	0.000252	CcSEcCtD
Sitaxentan—Feeling abnormal—Betaxolol—glaucoma	9.77e-05	0.000252	CcSEcCtD
Sitaxentan—Confusional state—Timolol—glaucoma	9.77e-05	0.000252	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—EDN1—glaucoma	9.76e-05	0.000827	CbGpPWpGaD
Sitaxentan—Oedema—Timolol—glaucoma	9.69e-05	0.00025	CcSEcCtD
Sitaxentan—Infection—Timolol—glaucoma	9.62e-05	0.000249	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NGFR—glaucoma	9.59e-05	0.000812	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Timolol—glaucoma	9.5e-05	0.000245	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—NARFL—glaucoma	9.44e-05	0.000799	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA5A—glaucoma	9.44e-05	0.000799	CbGpPWpGaD
Sitaxentan—Urticaria—Betaxolol—glaucoma	9.42e-05	0.000243	CcSEcCtD
Sitaxentan—Skin disorder—Timolol—glaucoma	9.41e-05	0.000243	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTM1—glaucoma	9.41e-05	0.000797	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—C3—glaucoma	9.39e-05	0.000795	CbGpPWpGaD
Sitaxentan—Body temperature increased—Betaxolol—glaucoma	9.37e-05	0.000242	CcSEcCtD
Sitaxentan—Diarrhoea—Clonidine—glaucoma	9.32e-05	0.000241	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTM1—glaucoma	9.28e-05	0.000786	CbGpPWpGaD
Sitaxentan—Anorexia—Timolol—glaucoma	9.23e-05	0.000238	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NTRK1—glaucoma	9.11e-05	0.000772	CbGpPWpGaD
Sitaxentan—Hypotension—Timolol—glaucoma	9.05e-05	0.000234	CcSEcCtD
Sitaxentan—Dizziness—Clonidine—glaucoma	9.01e-05	0.000233	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—GSTT1—glaucoma	8.88e-05	0.000752	CbGpPWpGaD
Sitaxentan—Insomnia—Timolol—glaucoma	8.76e-05	0.000226	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SMO—glaucoma	8.75e-05	0.000741	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Betaxolol—glaucoma	8.74e-05	0.000226	CcSEcCtD
Sitaxentan—Vomiting—Clonidine—glaucoma	8.66e-05	0.000224	CcSEcCtD
Sitaxentan—Somnolence—Timolol—glaucoma	8.61e-05	0.000222	CcSEcCtD
Sitaxentan—Rash—Clonidine—glaucoma	8.59e-05	0.000222	CcSEcCtD
Sitaxentan—Dermatitis—Clonidine—glaucoma	8.58e-05	0.000222	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTM1—glaucoma	8.58e-05	0.000726	CbGpPWpGaD
Sitaxentan—Headache—Clonidine—glaucoma	8.53e-05	0.00022	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—C3—glaucoma	8.53e-05	0.000722	CbGpPWpGaD
Sitaxentan—Dyspepsia—Timolol—glaucoma	8.53e-05	0.00022	CcSEcCtD
Sitaxentan—Asthenia—Betaxolol—glaucoma	8.51e-05	0.00022	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTM1—glaucoma	8.46e-05	0.000716	CbGpPWpGaD
Sitaxentan—Decreased appetite—Timolol—glaucoma	8.42e-05	0.000217	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CDKN2B—glaucoma	8.4e-05	0.000711	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Timolol—glaucoma	8.36e-05	0.000216	CcSEcCtD
Sitaxentan—Fatigue—Timolol—glaucoma	8.35e-05	0.000216	CcSEcCtD
Sitaxentan—Pain—Timolol—glaucoma	8.28e-05	0.000214	CcSEcCtD
Sitaxentan—Diarrhoea—Betaxolol—glaucoma	8.11e-05	0.00021	CcSEcCtD
Sitaxentan—Nausea—Clonidine—glaucoma	8.09e-05	0.000209	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—EDN1—glaucoma	8.06e-05	0.000682	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NTRK2—glaucoma	8e-05	0.000677	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Timolol—glaucoma	7.98e-05	0.000206	CcSEcCtD
Sitaxentan—Dizziness—Betaxolol—glaucoma	7.84e-05	0.000202	CcSEcCtD
Sitaxentan—Urticaria—Timolol—glaucoma	7.7e-05	0.000199	CcSEcCtD
Sitaxentan—Body temperature increased—Timolol—glaucoma	7.66e-05	0.000198	CcSEcCtD
Sitaxentan—Vomiting—Betaxolol—glaucoma	7.54e-05	0.000195	CcSEcCtD
Sitaxentan—Rash—Betaxolol—glaucoma	7.48e-05	0.000193	CcSEcCtD
Sitaxentan—Dermatitis—Betaxolol—glaucoma	7.47e-05	0.000193	CcSEcCtD
Sitaxentan—Headache—Betaxolol—glaucoma	7.43e-05	0.000192	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NGF—glaucoma	7.41e-05	0.000627	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Timolol—glaucoma	7.14e-05	0.000184	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—CYP1B1—glaucoma	7.08e-05	0.000599	CbGpPWpGaD
Sitaxentan—Nausea—Betaxolol—glaucoma	7.04e-05	0.000182	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—C3—glaucoma	7.04e-05	0.000596	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	6.98e-05	0.000591	CbGpPWpGaD
Sitaxentan—Asthenia—Timolol—glaucoma	6.95e-05	0.000179	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NGFR—glaucoma	6.86e-05	0.000581	CbGpPWpGaD
Sitaxentan—Diarrhoea—Timolol—glaucoma	6.63e-05	0.000171	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—APOE—glaucoma	6.55e-05	0.000555	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NTRK1—glaucoma	6.52e-05	0.000552	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CAV1—glaucoma	6.49e-05	0.00055	CbGpPWpGaD
Sitaxentan—Dizziness—Timolol—glaucoma	6.41e-05	0.000165	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—CA5A—glaucoma	6.22e-05	0.000527	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NARFL—glaucoma	6.22e-05	0.000527	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FN1—glaucoma	6.18e-05	0.000523	CbGpPWpGaD
Sitaxentan—Vomiting—Timolol—glaucoma	6.16e-05	0.000159	CcSEcCtD
Sitaxentan—Rash—Timolol—glaucoma	6.11e-05	0.000158	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—BAD—glaucoma	6.11e-05	0.000517	CbGpPWpGaD
Sitaxentan—Dermatitis—Timolol—glaucoma	6.1e-05	0.000158	CcSEcCtD
Sitaxentan—Headache—Timolol—glaucoma	6.07e-05	0.000157	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CDKN2B—glaucoma	6.01e-05	0.000509	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EDN1—glaucoma	5.77e-05	0.000488	CbGpPWpGaD
Sitaxentan—Nausea—Timolol—glaucoma	5.75e-05	0.000149	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—GSTM1—glaucoma	5.66e-05	0.000479	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	5.58e-05	0.000472	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NGF—glaucoma	5.3e-05	0.000449	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA1—glaucoma	5.05e-05	0.000428	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—C3—glaucoma	5.04e-05	0.000427	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOS3—glaucoma	4.91e-05	0.000416	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CTSA—glaucoma	4.9e-05	0.000415	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APOE—glaucoma	4.69e-05	0.000397	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CAV1—glaucoma	4.65e-05	0.000394	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA2—glaucoma	4.62e-05	0.000391	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA1—glaucoma	4.61e-05	0.00039	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	4.52e-05	0.000383	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	4.52e-05	0.000383	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CTSA—glaucoma	4.46e-05	0.000378	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FN1—glaucoma	4.42e-05	0.000375	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BAD—glaucoma	4.37e-05	0.00037	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1B—glaucoma	4.25e-05	0.00036	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA2—glaucoma	4.22e-05	0.000357	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	4.12e-05	0.000349	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	4.12e-05	0.000349	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—glaucoma	3.94e-05	0.000334	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—glaucoma	3.54e-05	0.0003	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOS3—glaucoma	3.51e-05	0.000298	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TXN—glaucoma	3.26e-05	0.000276	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—glaucoma	3.04e-05	0.000258	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA1—glaucoma	3.04e-05	0.000257	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.97e-05	0.000252	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TXN—glaucoma	2.97e-05	0.000251	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.94e-05	0.000249	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CTSA—glaucoma	2.94e-05	0.000249	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—glaucoma	2.82e-05	0.000239	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA2—glaucoma	2.78e-05	0.000235	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.71e-05	0.000229	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.69e-05	0.000227	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—glaucoma	2.67e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—glaucoma	2.53e-05	0.000214	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—glaucoma	2.53e-05	0.000214	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—glaucoma	2.3e-05	0.000195	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	2.04e-05	0.000172	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCA1—glaucoma	2.01e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1B1—glaucoma	2.01e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TXN—glaucoma	1.96e-05	0.000166	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—glaucoma	1.91e-05	0.000162	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.86e-05	0.000157	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCA1—glaucoma	1.83e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1B1—glaucoma	1.83e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—glaucoma	1.61e-05	0.000136	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—glaucoma	1.52e-05	0.000129	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—glaucoma	1.47e-05	0.000124	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTHFR—glaucoma	1.42e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—APOE—glaucoma	1.32e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CAV1—glaucoma	1.31e-05	0.000111	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTHFR—glaucoma	1.3e-05	0.00011	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCA1—glaucoma	1.21e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1B1—glaucoma	1.21e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APOE—glaucoma	1.21e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CAV1—glaucoma	1.2e-05	0.000101	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NOS3—glaucoma	9.92e-06	8.4e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—glaucoma	9.67e-06	8.19e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—glaucoma	9.07e-06	7.68e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NOS3—glaucoma	9.04e-06	7.66e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTHFR—glaucoma	8.55e-06	7.24e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—glaucoma	8.27e-06	7e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APOE—glaucoma	7.96e-06	6.74e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CAV1—glaucoma	7.89e-06	6.68e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NOS3—glaucoma	5.96e-06	5.05e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—glaucoma	5.45e-06	4.62e-05	CbGpPWpGaD
